Chat with us, powered by LiveChat

RenalytixAI & EKF Diagnostics win the AIM Transaction of the Year Award

N+1 Singer are delighted to announce that our client’s RenalytixAI and EKF Diagnostics have won the ‘AIM Transaction of the Year’ Award at the AIM Awards Dinner 2019.  

The award was won for RenalytixAI’s IPO on AIM last year, which raised gross funds of £22.25 million on admission. RenalytixAI is a spin out from EKF, the AIM-traded medical diagnostics business.

N+1 Singer is acting as Nominated Adviser and Broker to EKF Diagnostics and acted as RenalytixAI’s Nominated Adviser & Broker in relation to their admission to trading.

About The AIM Awards Dinner

The AIM Award Dinner attracts over 1,400 guests each year, including Senior Directors, Nomads, brokers and accountants to celebrate the outstanding achievements on the AIM market. The night identifies the quoted companies and entrepreneurs who have harnessed AIM to help them fulfill their ambitions and growth potential within the previous 12 months.

 

For more information about this news, please email us or call us on +44 (0)20 7496 3000.